The role of pharmacists in the delivery of cancer care has changed significantly in Ireland over recent years. These changes are largely due to increases in the use of chemotherapy as a result of the aging population, and supportive therapy for the management of side effects and co-morbidities. The overarching goal of the course is to educate pharmacists on the basics of lymphoma; non-Hodgkin’s lymphoma and multiple myeloma to better prepare them to recognize and treat these conditions within their clinical practice, to improve patient outcomes, and to be successful. Adverse prognostic factors including time to relapse, poor performance status, advanced stages at relapse and anemia have been shown to have an impact on survival and freedom from second relapse. This educational activity will review the newer treatment options for newly diagnosed patients taking into consideration recent guideline recommendations. Strategies for the management of patients who develop adverse effects and treatment complications will also be explained.